For example, Liu et al. in a study with 365 metastatic EGFR-mutant NSCLC patients received osimertinib ± aspirin and found that a combination of aspirin with osimertinib could improve the progression-free survival (PFS) and OS [15]; similarly, Aiad et al. in a study with 500 stages I–IV patients received immunotherapies ± aspirin and also found that the combination of aspirin could extend the outcome [16]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.